BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sakuma T, Masaki K, Abe-chayama H, Mochida K, Yamamoto T, Chayama K. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus. Genes Cells 2016;21:1253-62. [DOI: 10.1111/gtc.12437] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Soppe JA, Lebbink RJ. Antiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans. Trends in Microbiology 2017;25:833-50. [DOI: 10.1016/j.tim.2017.04.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
2 Cebrian-Serrano A, Davies B. CRISPR-Cas orthologues and variants: optimizing the repertoire, specificity and delivery of genome engineering tools. Mamm Genome 2017;28:247-61. [PMID: 28634692 DOI: 10.1007/s00335-017-9697-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 10.6] [Reference Citation Analysis]
3 Martinez MG, Combe E, Inchauspe A, Mangeot PE, Delberghe E, Chapus F, Neveu G, Alam A, Carter K, Testoni B, Zoulim F. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants. mBio 2022;:e0288821. [PMID: 35389262 DOI: 10.1128/mbio.02888-21] [Reference Citation Analysis]
4 Escalona-Noguero C, López-Valls M, Sot B. CRISPR/Cas technology as a promising weapon to combat viral infections. Bioessays 2021;43:e2000315. [PMID: 33569817 DOI: 10.1002/bies.202000315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Duraisamy GS, Bhosale D, Lipenská I, Huvarova I, Růžek D, Windisch MP, Miller AD. Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going? Viruses 2020;12:E998. [PMID: 32906840 DOI: 10.3390/v12090998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Smith T, Singh P, Chmielewski KO, Bloom K, Cathomen T, Arbuthnot P, Ely A. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses 2021;13:1344. [PMID: 34372550 DOI: 10.3390/v13071344] [Reference Citation Analysis]
7 Bellizzi A, Ahye N, Jalagadugula G, Wollebo HS. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System. J Neuroimmune Pharmacol 2019;14:578-94. [PMID: 31512166 DOI: 10.1007/s11481-019-09878-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Rodríguez-Rodríguez DR, Ramírez-Solís R, Garza-Elizondo MA, Garza-Rodríguez ML, Barrera-Saldaña HA. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review). Int J Mol Med 2019;43:1559-74. [PMID: 30816503 DOI: 10.3892/ijmm.2019.4112] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
9 Ramirez-Phillips AC, Liu D. Therapeutic Genome Editing and In Vivo Delivery. AAPS J 2021;23:80. [PMID: 34080099 DOI: 10.1208/s12248-021-00613-w] [Reference Citation Analysis]
10 Watanabe T, Inoue T, Tanaka Y. Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. Microorganisms 2021;9:2083. [PMID: 34683404 DOI: 10.3390/microorganisms9102083] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Qin K, Liang X, Sun G, Shi X, Wang M, Liu H, Chen Y, Liu X, He Z. Highly efficient correction of structural mutations of 450 kb KIT locus in kidney cells of Yorkshire pig by CRISPR/Cas9. BMC Mol Cell Biol 2019;20:4. [PMID: 31041890 DOI: 10.1186/s12860-019-0184-5] [Reference Citation Analysis]
12 Moyo B, Bloom K, Scott T, Ely A, Arbuthnot P. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res 2018;244:311-20. [PMID: 28087399 DOI: 10.1016/j.virusres.2017.01.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
13 Dong Z, Qin Q, Hu Z, Chen P, Huang L, Zhang X, Tian T, Lu C, Pan M. Construction of a One-Vector Multiplex CRISPR/Cas9 Editing System to Inhibit Nucleopolyhedrovirus Replication in Silkworms. Virol Sin 2019;34:444-53. [PMID: 31218589 DOI: 10.1007/s12250-019-00121-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Kurihara T, Fukuhara T, Ono C, Yamamoto S, Uemura K, Okamoto T, Sugiyama M, Motooka D, Nakamura S, Ikawa M, Mizokami M, Maehara Y, Matsuura Y. Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9. Sci Rep 2017;7:6122. [PMID: 28733609 DOI: 10.1038/s41598-017-05905-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
15 Ebrahimi S, Teimoori A, Khanbabaei H, Tabasi M. Harnessing CRISPR/Cas 9 System for manipulation of DNA virus genome. Rev Med Virol 2019;29:e2009. [PMID: 30260068 DOI: 10.1002/rmv.2009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
16 Balan V, Wang J. The CRISPR System and Cancer Immunotherapy Biomarkers. Methods Mol Biol 2020;2055:301-22. [PMID: 31502158 DOI: 10.1007/978-1-4939-9773-2_14] [Reference Citation Analysis]
17 Inoue T, Tanaka Y. The Role of Hepatitis B Core-Related Antigen. Genes (Basel) 2019;10:E357. [PMID: 31075974 DOI: 10.3390/genes10050357] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
18 Stone D, Long KR, Loprieno MA, De Silva Feelixge HS, Kenkel EJ, Liley RM, Rapp S, Roychoudhury P, Nguyen T, Stensland L, Colón-Thillet R, Klouser LM, Weber ND, Le C, Wagoner J, Goecker EA, Li AZ, Eichholz K, Corey L, Tyrrell DL, Greninger AL, Huang ML, Polyak SJ, Aubert M, Sagartz JE, Jerome KR. CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. Mol Ther Methods Clin Dev 2021;20:258-75. [PMID: 33473359 DOI: 10.1016/j.omtm.2020.11.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Lee C. CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge. Molecules 2019;24:E1349. [PMID: 30959782 DOI: 10.3390/molecules24071349] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
20 He ZY, Men K, Qin Z, Yang Y, Xu T, Wei YQ. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field. Sci China Life Sci 2017;60:458-67. [PMID: 28527117 DOI: 10.1007/s11427-017-9033-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
21 Yang YC, Yang HC. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas. Viruses 2021;14:4. [PMID: 35062208 DOI: 10.3390/v14010004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Jacobs R, Singh P, Smith T, Arbuthnot P, Maepa MB. Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases. Gene Ther 2022. [PMID: 35606493 DOI: 10.1038/s41434-022-00342-5] [Reference Citation Analysis]
23 Kostyushev DS, Zueva AP, Brezgin SA, Lipatnikov AD, Simirskii VN, Glebe D, Volchkova EV, Shipulin GA, Chulanov VP. [Overexpression of DNA-methyltransferases in persistency of cccDNA pool in chronic hepatitis B]. Ter Arkh 2017;89:21-6. [PMID: 29260742 DOI: 10.17116/terarkh2017891121-26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Chen P, You L, Lu Y. Applications of CRISPR-Cas9 Technology in Translational Research on Solid-Tumor Cancers. CRISPR J 2018;1:47-54. [PMID: 31021191 DOI: 10.1089/crispr.2017.0001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Yang H, Chen P. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Research 2018;244:304-10. [DOI: 10.1016/j.virusres.2017.06.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
26 Zhang Y, Li Z, Milon Essola J, Ge K, Dai X, He H, Xiao H, Weng Y, Huang Y. Biosafety materials: ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system. Biosafety and Health 2022. [DOI: 10.1016/j.bsheal.2022.03.010] [Reference Citation Analysis]
27 Maepa MB, Bloom K, Ely A, Arbuthnot P. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets 2021;25:451-66. [PMID: 33843412 DOI: 10.1080/14728222.2021.1915990] [Reference Citation Analysis]
28 Bloom K, Maepa MB, Ely A, Arbuthnot P. Gene Therapy for Chronic HBV-Can We Eliminate cccDNA? Genes (Basel) 2018;9:E207. [PMID: 29649127 DOI: 10.3390/genes9040207] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
29 Shen L, Hua Y, Fu Y, Li J, Liu Q, Jiao X, Xin G, Wang J, Wang X, Yan C, Wang K. Rapid generation of genetic diversity by multiplex CRISPR/Cas9 genome editing in rice. Sci China Life Sci 2017;60:506-15. [DOI: 10.1007/s11427-017-9008-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
30 Horie N, Hikita A, Nishizawa S, Uto S, Takato T, Hoshi K. Impairment of the transition from proliferative stage to prehypertrophic stage in chondrogenic differentiation of human induced pluripotent stem cells harboring the causative mutation of achondroplasia in fibroblast growth factor receptor 3. Regen Ther 2017;6:15-20. [PMID: 30271835 DOI: 10.1016/j.reth.2016.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
31 Trevisan M, Palù G, Barzon L. Genome editing technologies to fight infectious diseases. Expert Rev Anti Infect Ther 2017;15:1001-13. [PMID: 29090592 DOI: 10.1080/14787210.2017.1400379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
32 Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes (Basel) 2018;9:E483. [PMID: 30301171 DOI: 10.3390/genes9100483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Thompson DB, Aboulhouda S, Hysolli E, Smith CJ, Wang S, Castanon O, Church GM. The Future of Multiplexed Eukaryotic Genome Engineering. ACS Chem Biol 2018;13:313-25. [PMID: 29241002 DOI: 10.1021/acschembio.7b00842] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
34 El-Kenawy A, Benarba B, Neves AF, de Araujo TG, Tan BL, Gouri A. Gene surgery: Potential applications for human diseases. EXCLI J 2019;18:908-30. [PMID: 31762718 DOI: 10.17179/excli2019-1833] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
35 Khan S, Mahmood MS, Rahman SU, Zafar H, Habibullah S, Khan Z, Ahmad A. CRISPR/Cas9: the Jedi against the dark empire of diseases. J Biomed Sci 2018;25:29. [PMID: 29592810 DOI: 10.1186/s12929-018-0425-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
36 Lin H, Li G, Peng X, Deng A, Ye L, Shi L, Wang T, He J. The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses. Front Cell Infect Microbiol 2021;11:590989. [PMID: 34513721 DOI: 10.3389/fcimb.2021.590989] [Reference Citation Analysis]
37 Teng M, Yao Y, Nair V, Luo J. Latest Advances of Virology Research Using CRISPR/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development. Viruses 2021;13:779. [PMID: 33924851 DOI: 10.3390/v13050779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Yin L, Hu S, Mei S, Sun H, Xu F, Li J, Zhu W, Liu X, Zhao F, Zhang D, Cen S, Liang C, Guo F. CRISPR/Cas9 Inhibits Multiple Steps of HIV-1 Infection. Human Gene Therapy 2018;29:1264-76. [DOI: 10.1089/hum.2018.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
39 Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
40 Kostyushev D, Kostyusheva A, Ponomareva N, Brezgin S, Chulanov V. CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers. Nucleic Acid Ther 2021. [PMID: 34797701 DOI: 10.1089/nat.2021.0075] [Reference Citation Analysis]
41 Ko C, Michler T, Protzer U. Novel viral and host targets to cure hepatitis B. Current Opinion in Virology 2017;24:38-45. [DOI: 10.1016/j.coviro.2017.03.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]